Genelux Corporation’s platform technology technology has a vast array of applications to allow highly specific targeting and destruction of cancer cells. Our viruses can work alone (as a monotherapy), synergistically with existing marketed therapies as a combination therapy (including chemo, radiation therapy, monoclonal antibodies, etc.), or as a customized vector designed to over-express desired therapeutic, imaging or immune-rebuilding transgenes directly within the tumor. The company has also developed a separate line of veterinary-use oncolytic viruses which are currently under clinical evaluation in canine cancers.